A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: Modulation of megakaryocytic differentiation of K562 cells

被引:93
作者
Herrera, R
Hubbell, S
Decker, S
Petruzzelli, L
机构
[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Dept Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA
关键词
D O I
10.1006/excr.1997.3847
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In vitro megakaryocytic differentiation of the pluripotent K562 human leukemia cell line is induced by PMA. Treatment of K562 cells with PMA results in growth arrest, polyploidy, morphological changes, and increased cell-cell and cell-substrate adhesion. These PMA-induced changes in K562 cells are preceded by a rapid rise in the activity of MEK (MAP kinase/extracellular regulated kinases) that leads to a sustained activation of ERK2 (extracellular regulated kinase; MAPK). Blockade of MEK1 activation by PD098059, a recently described specific MEK inhibitor [D. T. Dudley ct al. (1995). Proc. Natl. Acad. Sci. USA 92, 7686-7689], reverses both the growth arrest and the morphological changes of K562 cells induced by PMA treatment. These changes are not associated with a disruption of PMA-induced down-regulation of BCR-ABL kinase or early integrin signaling events but are associated with a block of the cell-surface expression of the gpIIb/IIIa (CD41) integrin, a cell marker of megakaryocytic differentiation. These results demonstrate that the PMA-induced signaling cascade initiated by protein kinase C activation requires the activity of the MEK/ERK signaling complex to regulate cell cycle arrest, thus regulating the program that leads to the cell-surface expression of markers associated with megakaryocytic differentiation. (C) 1998 Academic Press.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 65 条
[1]   SELECTIVE REQUIREMENT FOR MAP KINASE ACTIVATION IN THYMOCYTE DIFFERENTIATION [J].
ALBEROLAILA, J ;
FORBUSH, KA ;
SEGER, R ;
KREBS, EG ;
PERLMUTTER, RM .
NATURE, 1995, 373 (6515) :620-623
[2]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[3]  
ALITALO R, 1990, BLOOD, V75, P1974
[4]   INDUCED-DIFFERENTIATION OF K562 LEUKEMIA-CELLS - A MODEL FOR STUDIES OF GENE-EXPRESSION IN EARLY MEGAKARYOBLASTS [J].
ALITALO, R .
LEUKEMIA RESEARCH, 1990, 14 (06) :501-&
[5]   SIGNAL-TRANSDUCTION VIA THE MAP KINASES - PROCEED AT YOUR OWN RSK [J].
BLENIS, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :5889-5892
[6]   A GAIN-OF-FUNCTION MUTATION IN DROSOPHILA MAP KINASE ACTIVATES MULTIPLE RECEPTOR TYROSINE KINASE SIGNALING PATHWAYS [J].
BRUNNER, D ;
OELLERS, N ;
SZABAD, J ;
BIGGS, WH ;
ZIPURSKY, SL ;
HAFEN, E .
CELL, 1994, 76 (05) :875-888
[7]   INDUCED CELL-SURFACE EXPRESSION OF FUNCTIONAL ALPHA-2-BETA-1-INTEGRIN DURING MEGAKARYOCYTIC DIFFERENTIATION OF K562 LEUKEMIC-CELLS [J].
BURGER, SR ;
ZUTTER, MM ;
STURGILLKOSZYCKI, S ;
SANTORO, SA .
EXPERIMENTAL CELL RESEARCH, 1992, 202 (01) :28-35
[8]  
BUSCHER D, 1995, MOL CELL BIOL, V15, P466
[9]  
BUTLER TM, 1990, CANCER RES, V50, P6323
[10]  
CAMPBELL ML, 1993, CELL GROWTH DIFFER, V4, P581